MIRO · Miromatrix Medical Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.2K | $8.5K | $8.0K | - | $12.4K | $4.0K | $6.1K | - | $9.8K | $9.4K |
| Cost of Revenue | $125.0K | $125.0K | $125.0K | - | $125.0K | $125.0K | $125.0K | - | $125.0K | $125.0K |
| Gross Profit | ($113.8K) | ($116.5K) | ($117.0K) | - | ($112.6K) | ($121.0K) | ($118.2K) | - | ($115.2K) | ($115.6K) |
| R&D | $3.51M | $3.62M | $4.39M | - | $4.57M | $4.99M | $1.87M | - | $3.35M | $2.48M |
| SG&A | $2.14M | $2.04M | $2.60M | - | $2.05M | $2.19M | $562.9K | - | $460.1K | $786.3K |
| Total Operating Expenses | $6.52M | $6.57M | $7.98M | - | $7.64M | $8.11M | $7.07M | - | $5.09M | $3.46M |
| D&A | $288.1K | $289.4K | $289.9K | - | $281.3K | $273.6K | $30.0K | - | $34.4K | $37.1K |
| Operating Income | ($6.64M) | ($6.69M) | ($8.10M) | - | ($7.76M) | ($8.23M) | ($7.19M) | - | ($5.21M) | ($2.87M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($6.45M) | ($6.53M) | ($7.48M) | - | ($7.63M) | ($8.18M) | ($7.20M) | - | ($2.99M) | ($3.27M) |
| EPS - Basic | ($0.24) | ($0.24) | ($0.33) | - | ($0.37) | ($0.40) | ($0.35) | - | ($0.25) | ($1.50) |
| EPS - Diluted | ($0.24) | ($0.24) | ($0.33) | - | ($0.37) | ($0.40) | ($0.35) | - | ($0.25) | ($1.50) |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.12M | $4.57M | $13.62M | $5.21M | $5.54M | $12.59M | $44.68M | $52.81M | $62.09M | $66.53M |
| Accounts Receivable | $11.2K | $930.4K | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.05M | $803.6K | $1.17M | $1.58M | $1.16M | $1.08M | $478.9K | $2.09M | $1.25M | $130.2K |
| Current Assets | $17.19M | $21.88M | $27.35M | $27.31M | $32.84M | $33.96M | $46.14M | $55.34M | $62.55M | $4.69M |
| Total Assets | $23.42M | $28.45M | $34.24M | $34.76M | $40.61M | $47.65M | $53.96M | $60.93M | $64.23M | $67.12M |
| Current Liabilities | $4.97M | $3.89M | $3.33M | $4.95M | $4.06M | $3.74M | $2.49M | $4.56M | $3.56M | $8.16M |
| Long-term Debt | $386.0K | $386.0K | $386.0K | $386.0K | $386.0K | $386.0K | $386.0K | $386.0K | - | - |
| Total Liabilities | $7.88M | $6.90M | $6.44M | $8.66M | $7.86M | $7.64M | $6.50M | $6.80M | $4.96M | $3.71M |
| Stockholders' Equity | $15.54M | $21.55M | $27.80M | $26.11M | $32.74M | $40.01M | $47.46M | $54.13M | ($50.12M) | ($51.03M) |
| Retained Earnings | ($124.48M) | ($118.02M) | ($111.49M) | ($104.01M) | ($97.07M) | ($89.44M) | ($81.26M) | ($74.05M) | ($68.58M) | ($59.38M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($8.62M) | - | - | - | ($2.18M) | - | - | - |
| Investing Cash Flow | - | - | $7.98M | - | - | - | $1.99M | - | - | - |
| Financing Cash Flow | - | - | $9.04M | - | - | - | $2.2K | - | - | - |
| CapEx | - | - | $15.5K | - | - | - | $5.9K | - | - | - |
| Free Cash Flow | - | - | ($8.63M) | - | - | - | ($2.18M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -1018.5% | -1367.7% | -1466.2% | - | -908.5% | -3063.0% | -1935.7% | - | -1173.0% | -1230.6% |
| Operating margin | -59369.1% | -78530.1% | -101478.9% | - | -62575.9% | -208362.0% | -117761.5% | - | -53046.3% | -30559.3% |
| EBITDA margin | -56791.2% | -75131.8% | -97846.1% | - | -60306.6% | -201438.7% | -117269.8% | - | -52695.9% | -30164.6% |
| Net margin | -57746.0% | -76675.1% | -93724.5% | - | -61541.4% | -207039.2% | -117939.6% | - | -30473.8% | -34842.2% |
| Free cash flow margin | - | - | -108156.2% | - | - | - | -35740.9% | - | - | - |
| FCF / Net income | - | - | 1.15 | - | - | - | 0.30 | - | - | - |
| R&D / Revenue | 31371.3% | 42517.6% | 55032.2% | - | 36906.3% | 126220.5% | 30582.9% | - | 34116.5% | 26409.3% |
| SG&A / Revenue | 19178.8% | 23924.9% | 32580.3% | - | 16561.0% | 55376.0% | 9215.4% | - | 4685.9% | 8370.5% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -27.6% | -23.0% | -21.8% | - | -18.8% | -17.2% | -13.4% | - | -4.7% | -4.9% |
| Return on equity | -41.5% | -30.3% | -26.9% | - | -23.3% | -20.4% | -15.2% | - | 6.0% | 6.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.46 | 5.63 | 8.22 | 5.52 | 8.09 | 9.09 | 18.54 | 12.12 | 17.58 | 0.57 |
| Quick ratio | 3.46 | 5.63 | 8.22 | 5.52 | 8.09 | 9.09 | 18.54 | 12.12 | 17.58 | 0.57 |
| Cash ratio | 1.23 | 1.18 | 4.10 | 1.05 | 1.36 | 3.37 | 17.95 | 11.57 | 17.45 | 8.15 |
| Leverage | ||||||||||
| Debt / Equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | - | - |
| Debt / Assets | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.51 | 1.32 | 1.23 | 1.33 | 1.24 | 1.19 | 1.14 | 1.13 | -1.28 | -1.32 |
| Liabilities / Assets | 0.34 | 0.24 | 0.19 | 0.25 | 0.19 | 0.16 | 0.12 | 0.11 | 0.08 | 0.06 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 365d | 39871d | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 3061d | 2346d | 3423d | - | 3380d | 3150d | 1398d | - | 3648d | 380d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -9.8% | 115.5% | 30.7% | - | 26.2% | -57.9% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -1.1% | 3.8% | 1.0% | - | 2.2% | -4.7% | - | - | - | - |
| Operating income growth (YoY) | 14.5% | 18.8% | -12.6% | - | -48.9% | -186.8% | - | - | - | - |
| Net income growth (YoY) | 15.4% | 20.2% | -3.8% | - | -154.9% | -150.0% | - | - | - | - |
| EPS growth (YoY) | 35.1% | 40.0% | 5.7% | - | -48.0% | 73.3% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -295.4% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -52.5% | -46.1% | -41.4% | -51.8% | - | - | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Miromatrix Medical Inc. against the 5 most active filers in the same SIC group.